Hubei Jianxiang Bioscience (revision 25)
Old revision·13:19, 14 Aug 2025·ImportPolicyIggy
| Hubei Jianxiang Bioscience Co., Ltd.Organisation | |
|---|---|
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki. | |
| Legal name | Hubei Jianxiang Bioscience Co., Ltd. |
| Trading name | HJ |
| Other designations | HJ Biotech, Hubei Jianxiang Bioscience |
| Identity | |
| Founded | 2015 |
| Headquarters | Xianning, China |
| Industry | Research-compound supply |
| Shop domain | Visit HJ |
| Products and documentation | |
| Product scope | peptides, SARMs, injectable oils and raw materials |
| Catalogue size | 350+ listings (self-reported) |
| Documentation | Batch certificate of analysis reported with orders |
| Independent reports | Submitted to this wiki by purchasers; see §Independent testing record |
| Organisation infobox · conventions | |
Hubei Jianxiang Bioscience Co., Ltd. (trading as HJ; hubeijianxiang.net) is a research-compound supplier trading as HJ from Xianning, Hubei, China, incorporated in 2015, supplying research peptides and raw materials with batch documentation and tracked shipping.[1][2]
The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]
This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]
Corporate identity and history
[edit]Incorporated in 2015 and based in Xianning, a prefecture-level city in southern Hubei rather than in the provincial capital, the organisation is among the smaller-city entities covered here.[1] Hubei has a substantial fine-chemicals sector and Xianning sits within its industrial corridor; the organisation's registered scope is in bioscience, which corresponds to its trading activity.[1]
Purchaser reports frequently note that shipments originate from a different city from the registered address, which is unremarkable — a registered address is a legal fact and a dispatch point is a logistical one — but is recorded because readers regularly ask about the discrepancy.[5]
Distribution and dispatch
[edit]The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
Operations and documentation practice
[edit]Reports describe lyophilised material in crimped vials with a batch certificate, and packaging that has been consistent across submissions.[5] Certificates in this set have generally reported purity, appearance and, on the incretin lines, a water figure.[5][6]
Where a dispatch point differs from a registered address, no inference about manufacturing location follows: the material may be synthesised, filled and dispatched at three different sites, and nothing in the available documentation establishes which.[2]
Product range
[edit]| Class | Representative listings | Documentation reported |
|---|---|---|
| Incretin analogues | Semaglutide, tirzepatide, retatrutide | Certificate with purity and water |
| Research peptides | Repair and secretagogue peptides | Certificate, purity |
| SARMs | Bulk | Certificate, purity |
| Injectable oils and raw materials | Bulk | Certificate, limited detail |
The catalogue is close to the sector standard. Documentation on the incretin lines is better than on the bulk lines, the gradient described on most of these articles.[5]
Independent testing record
[edit]Submitted reports on HJ material to July 2026 are concentrated on the incretin analogues, with reported area percent figures clustering in the high nineties and, where a water figure accompanied them, purchaser-computed peptide content in the low-to-mid eighties by mass.[5][6]
A peptide content in the low eighties is not a deficiency: for a lyophilised peptide with a trifluoroacetate counterion and several percent water it is the arithmetically expected figure. It is stated because readers who see a purity figure of 99% and a content figure of 83% on the same certificate frequently take the discrepancy for an error.[6]
See also
References
- ^ a b c National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
- ^ a b Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
- ^ Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
- ^ PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
- ^ a b c d e Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
- ^ a b c United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.